Novartis : to initiate SMART Phase 3b global study of Zolgensma in children up to 21 kg, building on real-world experience – marketscreener.com
CONTEXT: Novrtis going old school with the announcement of a global Phase 3b study in children with spinal muscular atrophy (SMA). Respect to Novartis for making the announcement and calling Continue Reading